Dr. Reddy's Laboratories Ltd (RDY): Price and Financial Metrics
Dr. Reddy's Laboratories Ltd (RDY)
Today's Latest Price: $47.25 USD
Updated Apr 8 1:15pm
Add RDY to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 214 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
RDY Stock Summary
- The price/operating cash flow metric for Dr Reddys Laboratories Ltd is higher than only 2.83% of stocks in our set with a positive cash flow.
- In terms of volatility of its share price, RDY is more volatile than merely 4.33% of stocks we're observing.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for RDY comes in at 311.01% -- higher than that of 98.18% of stocks in our set.
- Stocks that are quantitatively similar to RDY, based on their financial statements, market capitalization, and price volatility, are WBC, BRKR, GENC, NSSC, and MOG.A.
- RDY's SEC filings can be seen here. And to visit Dr Reddys Laboratories Ltd's official web site, go to www.drreddys.com.
RDY Stock Price Chart More Charts
RDY Price/Volume Stats
| Current price | $47.25 | 52-week high | $47.43 |
| Prev. close | $44.59 | 52-week low | $33.33 |
| Day low | $45.51 | Volume | 461,011 |
| Day high | $47.43 | Avg. volume | 217,821 |
| 50-day MA | $41.77 | Dividend yield | 0.58% |
| 200-day MA | $39.48 | Market Cap | 7.83B |
Dr. Reddy's Laboratories Ltd (RDY) Company Bio
Dr. Reddy's Laboratories operates as an integrated pharmaceutical company worldwide. It operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The company was founded in 1984 and is based in Hyderabad, India.
RDY Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $47.25 | $2119.45 | 4653% |
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Dr Reddys Laboratories Ltd. To summarize, we found that Dr Reddys Laboratories Ltd ranked in the 93th percentile in terms of potential gain offered. Moreover, under all the scenarios we modelled, the output consistently forecasted positive returns. The most interesting components of our discounted cash flow analysis for Dr Reddys Laboratories Ltd ended up being:
- The company has produced more trailing twelve month cash flow than 99.03% of its sector Healthcare.
- The business' balance sheet suggests that 7% of the company's capital is sourced from debt; this is greater than merely 16.45% of the free cash flow producing stocks we're observing.
- RDY's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 51.31% of tickers in our DCF set.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | 4560% |
| 1% | 4607% |
| 2% | 4653% |
| 3% | 4700% |
| 4% | 4746% |
| 5% | 4793% |
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as RDY, try USNU, HZNP, THC, SUPN, and BEAT.
Top Stories View All
Earnings Season Starts This Week, What to Expect
Best & Worst Performing Stock Industries for April 7, 2020
Best & Worst Performing Small Cap Stocks for April 7, 2020
Best & Worst Performing Mid Cap Stocks for April 7, 2020
Best & Worst Performing Large Cap Stocks for April 7, 2020
View All Top Stories
Loading social stream, please wait...